secwatch.observer — SEC 8-K summary
======================================

Issuer:     SIGA TECHNOLOGIES INC (SIGA)
CIK:        0001010086
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001140361-22-017858
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIGA Q1 revenue doubles to $10.5M; net loss narrows; declares special $0.45 dividend
--------------------------------------------------------------------------------

- Q1 total revenues $10.5M vs $4.8M YoY; operating loss improved to $1.4M from $2.0M.
- First IV TPOXX sales to U.S. govt under BARDA contract: $7M delivered in Q1.
- New Asia Pacific contract for ~$3M of oral TPOXX; PHAC contract increased $5M.
- Board declared special dividend of $0.45/share, payable June 2 to holders of record May 17.
- EMA approved oral tecovirimat for smallpox, monkeypox, cowpox, and vaccinia complications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1010086/000114036122017858/0001140361-22-017858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1010086/000114036122017858/brhc10037201_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-017858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer